One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1182/blood.v120.21.163.163
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 16, 2012 |
 Citations: 37 |
Affiliation: The University of Texas MD Anderson Cancer Center, Ariadne Diagnostics (United States), Charité - Universitätsmedizin Berlin, SunEdison (United States), Singapore General Hospital, Duke-NUS Medical School, Emory Healthcare, Jena University Hospital, Huntsman Cancer Institute, University of Utah, St. Eugenio Hospital, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, Washington University in St. Louis, Dana-Farber Cancer Institute, Michigan Center for Translational Pathology, University of Michigan–Ann Arbor, Seoul St. Mary's Hospital, Catholic University of Korea, University of Bologna, University of Milano-Bicocca, Imperial College London, Hammersmith Hospital, Moffitt Cancer Center, Hôpital Lyon Sud, Hôpital Saint-Louis, Inserm, South Australia Pathology, University of California, San Francisco
A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
